Related Experiment Video
Updated: Jul 12, 2026
07:10
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1
1AIDS Research Unit, National Institute for Virology, Sandringham, Johannesburg, South Africa. cgray@niv.ac.za
Archivum Immunologiae Et Therapiae Experimentalis
|November 4, 2000
Summary
Developing effective HIV-1 vaccines requires understanding immune responses for prevention and therapy. Affordable, high-efficacy vaccines are crucial for global HIV-1 control, especially in developing nations.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- An estimated 30.6 million people were living with HIV-1 in 1999, with 16,000 new infections daily.
- Over 90% of new HIV-1 infections occur in developing countries, necessitating affordable vaccine solutions.
- Current strategies focus on developing vaccines to combat the high rates of HIV-1 transmission.
Purpose of the Study:
- To review critical immune parameters for designing effective preventative HIV-1 vaccines.
- To examine mechanisms of immune destruction in HIV-1 infection for therapeutic vaccine development.
- To propose realistic goals for both preventative and therapeutic HIV-1 vaccine strategies.
Main Methods:
- Analysis of immune parameters crucial for eliciting protective immune responses.
- Examination of mechanisms underlying immune destruction during chronic HIV-1 infection.
- Review of vaccine strategies considering dendritic cell and Langerhan cell priming for cellular and humoral immunity.
Main Results:
- Preventative vaccines should elicit neutralizing antibodies (NAB) and cytotoxic T lymphocytes (CTL) to impede viral replication.
- Therapeutic vaccines require addressing persistent immune stimulation by reducing viral antigen presentation.
- Antiretroviral therapy may be transiently used to facilitate immune response to therapeutic vaccines.
Conclusions:
- Successful HIV-1 vaccine design must consider both preventative and therapeutic approaches.
- Eliciting robust cellular and humoral immunity through proper immune cell priming is key for preventative vaccines.
- Therapeutic strategies may involve short-course antiretroviral therapy to enhance immune responses in chronic HIV-1 infection.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:51Vaccinations
Overview
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...